BAYA Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €6.60 |
52 Week High | €15.60 |
52 Week Low | €6.30 |
Beta | 0.97 |
1 Month Change | -5.71% |
3 Month Change | -19.51% |
1 Year Change | -53.19% |
3 Year Change | -51.11% |
5 Year Change | -56.29% |
Change since IPO | -54.48% |
Recent News & Updates
Recent updates
Shareholder Returns
BAYA | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -0.8% | 2.3% | 1.9% |
1Y | -53.2% | -25.9% | 7.3% |
Return vs Industry: BAYA underperformed the German Pharmaceuticals industry which returned -25.9% over the past year.
Return vs Market: BAYA underperformed the German Market which returned 7.3% over the past year.
Price Volatility
BAYA volatility | |
---|---|
BAYA Average Weekly Movement | 8.3% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BAYA's share price has been volatile over the past 3 months.
Volatility Over Time: BAYA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1863 | 96,931 | Bill Anderson | https://www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
BAYA fundamental statistics | |
---|---|
Market cap | €27.92b |
Earnings (TTM) | -€2.94b |
Revenue (TTM) | €47.64b |
0.6x
P/S Ratio-9.5x
P/E RatioIs BAYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAYA income statement (TTM) | |
---|---|
Revenue | €47.64b |
Cost of Revenue | €19.75b |
Gross Profit | €27.89b |
Other Expenses | €30.83b |
Earnings | -€2.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | -2.99 |
Gross Margin | 58.55% |
Net Profit Margin | -6.17% |
Debt/Equity Ratio | 132.3% |
How did BAYA perform over the long term?
See historical performance and comparison